Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Receivables (2024 - 2025)

ImmunityBio (IBRX) has disclosed Change in Receivables for 4 consecutive years, with $10.6 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 681.54% to $10.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40.2 million through Dec 2025, up 1603.86% year-over-year, with the annual reading at $40.2 million for FY2025, 1603.86% up from the prior year.
  • Change in Receivables for Q4 2025 was $10.6 million at ImmunityBio, up from $9.9 million in the prior quarter.
  • The five-year high for Change in Receivables was $14.7 million in Q1 2025, with the low at -$1.8 million in Q4 2024.